Review
Open access
Oct 2026
SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
These findings support proactive, guideline-concordant initiation of evidence-based SGLT2i agents by endocrinologists, cardiologists and primary care providers as foundational therapy in type 2 diabetes mellitus.
Ahmed Elbataa, A. Mansour, Ahmed Elazab et al.
· Diabetes, obesity and metabo... · 0 citations